Elanco Animal Health (NYSE:ELAN) Stock Gets Price Target Increase from JPMorgan Chase & Co.

Elanco Animal Health (NYSE:ELAN) had its price target boosted by JPMorgan Chase & Co. from $33.00 to $35.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 30.48% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. UBS Group upped their target price on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Jefferies Financial Group downgraded Elanco Animal Health from a “buy” rating to a “hold” rating and dropped their target price for the company from $31.00 to $24.00 in a research report on Tuesday, October 20th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Monday. Finally, The Goldman Sachs Group assumed coverage on Elanco Animal Health in a research note on Friday, October 16th. They set a “buy” rating and a $32.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus price target of $29.75.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock traded up $1.08 on Monday, reaching $26.82. 5,524,143 shares of the stock were exchanged, compared to its average volume of 5,622,399. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The firm has a market cap of $13.40 billion, a PE ratio of -90.10, a P/E/G ratio of 2.28 and a beta of 1.73. The firm’s 50 day moving average is $23.13 and its 200-day moving average is $23.82. Elanco Animal Health has a one year low of $19.40 and a one year high of $27.98.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.07. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.21 billion. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.83%. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period last year, the firm posted $0.19 earnings per share. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. As a group, analysts anticipate that Elanco Animal Health will post 1.13 EPS for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, insider Shiv O’Neill acquired 3,998 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, August 18th. The shares were bought at an average price of $23.58 per share, with a total value of $94,272.84. Following the completion of the purchase, the insider directly owned 87,832 shares in the company, valued at $2,071,078.56. This trade represents a 4.77% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Timothy J. Bettington sold 4,350 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total value of $100,050.00. Following the completion of the sale, the insider owned 138,911 shares of the company’s stock, valued at $3,194,953. The trade was a 3.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders bought a total of 48,998 shares of company stock worth $1,139,373 over the last ninety days. Insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bessemer Group Inc. increased its holdings in Elanco Animal Health by 232.4% during the third quarter. Bessemer Group Inc. now owns 8,566 shares of the company’s stock worth $192,000 after buying an additional 5,989 shares during the last quarter. Harbour Investments Inc. boosted its stake in Elanco Animal Health by 304.1% in the third quarter. Harbour Investments Inc. now owns 2,053 shares of the company’s stock valued at $46,000 after acquiring an additional 1,545 shares during the last quarter. Trillium Asset Management LLC purchased a new position in Elanco Animal Health in the third quarter valued at about $3,135,000. Eurizon Capital SGR S.p.A. grew its position in shares of Elanco Animal Health by 139.8% during the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 92,821 shares of the company’s stock valued at $2,080,000 after acquiring an additional 54,111 shares during the period. Finally, Maryland State Retirement & Pension System grew its position in shares of Elanco Animal Health by 17.1% during the 3rd quarter. Maryland State Retirement & Pension System now owns 30,363 shares of the company’s stock valued at $680,000 after acquiring an additional 4,442 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health.

For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

The company traces its origins to Eli Lilly’s animal health business, established in 1954, and became an independent public company in 2018.